

About gastric cancer

Gastric cancer, including cancers of the gastroesophageal junction and esophagus, is the fifth most frequently diagnosed cancer worldwide.¹ Many cases of gastric cancer go undetected until they are advanced or metastatic (spread to other parts of the body), when treatment options can be limited.¹ That's why exploring potential treatment options through clinical research is so important.

About clinical research

The main reason for a clinical trial is to learn as much as possible about the safety and effectiveness of investigational treatments. These trials must be completed before a new treatment can be made available to the public. Every day, research uncovers new information about medical conditions and possible therapies. Right now, there are more than 500,000 clinical trials registered all over the world.²

About the ROSETTA Gastric-204 Trial

The purpose of this trial is to test how safe and effective an investigational treatment is for previously untreated advanced (at a late stage) or metastatic (spread to other parts of the body) gastric, gastroesophageal junction, or esophageal cancer. This trial will compare the combination of the investigational treatment and chemotherapy against a standard-of-care (SOC) treatment (treatment that is accepted and widely used by healthcare professionals, which includes chemotherapy) to evaluate if it could influence outcomes for people with these types of cancers.

Participants will receive either:

- The investigational treatment in combination with chemotherapy, which are given as an infusion (through a tiny tube in your vein) every 2 weeks, or
- The SOC treatment, nivolumab, in combination with chemotherapy, which are given as an infusion (through a tiny tube in your vein) every 2 weeks

Participants' total trial duration and number of visits will depend on their response to the trial treatment.

¹ <https://www.ncbi.nlm.nih.gov/books/NBK459142/>

² <https://clinicaltrials.gov/about-site/trends-charts>

Thank you for considering this trial

Managing gastric, gastroesophageal junction, or esophageal cancer will be different for everyone. The key is to be aware of your options. Researchers are exploring potential treatments for gastric, gastroesophageal junction, or esophageal cancer and being in a clinical trial may be an option for you.

The decision is yours, and if you'd like your doctor's advice, talk to them about clinical trial options for gastric, gastroesophageal junction, or esophageal cancer.

Ask your doctor questions such as:

- What kind of clinical trials are available for people with gastric, gastroesophageal junction, or esophageal cancer?
- Would you still be my doctor if I join a clinical trial?
- Could joining a trial for people with gastric, gastroesophageal junction, or esophageal cancer be an option for me?

Contact information:

This trial is being conducted by:



A clinical
trial for
gastric cancer



ROSETTA
GASTRIC-204

The ROSETTA Gastric-204 Trial (CA266-0004)
**Explore another approach
for gastric cancer**

Every journey with gastric, gastroesophageal junction, or esophageal cancer is different. Clinical researchers are working to expand the options available for previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal cancer—see if the **ROSETTA Gastric-204 Trial** is right for you.

BIONTECH |  Bristol Myers Squibb®

The image depicted contains models and is being used for illustrative purposes only.

Trial design

Trial participation is divided into 3 sections:

Screening period

- Potential participants provide consent to participate in the trial.
- They are screened to see if they qualify for the trial, which may include tests and office visits.

Treatment period

- Participants receive their assigned trial treatment. The total length of this period will depend on each participant's response to their trial treatment.

Follow-up period

The follow-up period includes 3 parts:

- A safety check-up about 1 month after the last dose of the trial treatment
- A safety check-up about 3 months after the last dose of the trial treatment
- Long-term follow-ups every 3 months or more often if needed



Am I eligible?

You may be eligible to join the **ROSETTA-Gastric-204 Trial** if you:



Are at least **18 years old**



Have untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal cancer

- **Metastatic:** Cancer that has spread to other parts of the body
- **Advanced:** Cancer that is at a late stage



Have not previously received systemic anti-cancer therapy for your gastric, gastroesophageal junction, or esophageal cancer

- **Systemic therapy:** Treatment that travels through your bloodstream and is given by tablet or injection

Your trial doctor can tell you about other requirements for joining the trial.

Qualified participants will receive all trial-related care and the investigational treatment, if assigned to them, at no cost.

Reimbursement for travel and expenses may be provided.

The importance
of representation
in research

Why participate?

By participating in the **ROSETTA Gastric-204 Trial**, you:

- Could help enable doctors and researchers to learn more about the investigational treatment being evaluated in this trial
- Will receive trial-related care from experienced medical professionals
- May help others by contributing to medical research



The images depicted contain models and are being used for illustrative purposes only.

Research has shown that certain diseases and treatments may affect people differently based on several factors, including social determinants of health.¹ For this reason, it is important that people from all backgrounds be involved in medical research.

¹ <https://my.clevelandclinic.org/health/articles/social-determinants-of-health>